GLP-1s: Turning the Tables on Type 2 Diabetes

Diabetes is a persistent ailment that afflicts myriad individuals globally. Type 2 diabetes, in particular, has become a significant public health challenge due to its increasing prevalence and association with obesity and a sedentary lifestyle. Nonetheless, a novel group of treatments has surfaced, instilling optimism for the management and prophylaxis of type 2 diabetes - GLP-1s (glucagon-like peptide 1).

When the levels of sugar in the blood begin to rise, GLP-1s are injectable drugs that trigger the body to create more insulin. This assists in the management of diabetic symptoms, the improvement of blood sugar control, and the reduction of the risk of consequences such as heart disease, damage to the nerves, and blindness. Unlike other diabetes medications, GLP-1s also promote weight loss and can reduce the risk of hypoglycemia (low blood sugar levels).

The introduction of GLP-1s has revolutionized the type 2 diabetes space. The market is expected to grow as more patients are diagnosed with type 2 diabetes and seek effective treatment options. As a result, both Eli Lilly and Novo Nordisk, two major players in the diabetes market, are expanding their GLP-1 portfolios to meet the growing demand.
Eli Lilly, in particular, is doubling its capacity to produce GLP-1s by the end of 2023. This expansion includes investments in manufacturing facilities, research and development, and clinical trials. The company is committed to advancing diabetes care by developing innovative treatments that address the unmet needs of patients. This includes expanding its GLP-1 portfolio with new medications such as tirzepatide, which has shown promising results in clinical trials for weight loss and blood sugar control.
Similarly, Novo Nordisk is also investing in the development and commercialization of GLP-1s. The company has a robust pipeline of diabetes therapies, including semaglutide, a once-weekly GLP-1 injection that has been approved for the treatment of type 2 diabetes and obesity. Novo Nordisk is also exploring the potential of oral GLP-1s, which could provide a more convenient treatment option for patients.

GLP-1s provide numerous advantages in both treatment and averting type 2 diabetes, like improved blood sugar management, weight loss, and a lower risk of complications. As more patients are diagnosed with type 2 diabetes, the demand for effective treatment options is expected to grow, creating a significant market opportunity for GLP-1 manufacturers. With ongoing investments in research and development, manufacturing, and clinical trials, the future looks bright for GLP-1s in the fight against type 2 diabetes.

This class of medications can also aid in reducing hunger, which expands the market for them in relation to obesity. An overall trend in health care that places greater emphasis on treating the causes of diseases like diabetes and cardiovascular disease rather than their symptoms is expected to be especially beneficial for the sector. According to studies, type 2 diabetes is 80 times more likely to affect obese people than non-obese persons, and obesity is responsible for 80 to 85% of the risk of acquiring the disease. Patients with prediabetes, for instance, might gain from such therapies. According to estimates, there are roughly twice as many prediabetics as type 2 diabetics in the United States, where there are 30 million patients with the condition.

The clinical trial SURMOUNT-1 conducted by Lily's Mounjaro exhibited encouraging outcomes. Patients saw average weight reductions of 16%, 21.4%, and 22.5% at dosages of 5 mg, 10 mg, and 15 mg, respectively. The outcomes outperformed those of Novo Nordisk's diabetes medication Ozempic, sold to obese patients as Wegovy, which in clinical studies assisted patients in losing an average of 12.4% of their body weight against placebo.

Because Mounjaro's efficacy findings compare favourably to standard surgical procedures, the medical community is hopeful about Mounjaro and its potential impact on the obesity industry. Both gastric bypass and sleeve gastrectomy procedures have considerable risks and can cost up to $30,000, yet they normally produce average weight reductions of 20% and 25%–30%, respectively.It is anticipated that 38 GLP-1s would be crucial in combating the global obesity pandemic.

BioIntel360 foresees that GLP-1s have transformed the therapy and prophylaxis of type 2 diabetes by furnishing patients with a potent approach to regulate their blood glucose levels. The development of this new class of therapies has not only improved patient outcomes but also offered hope for a better future. The demand for these therapies is expected to grow. It is reassuring to know that both Eli Lilly and Novo Nordisk are looking to expand supply capacity of their GLP-1 portfolios to meet the increasing demand. The future looks bright for the treatment and prevention of type 2 diabetes with GLP-1s leading the way.